A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
CTT Nguyen, F Petrelli, S Scuri, BT Nguyen… - The European Journal of …, 2019 - Springer
Objective To review and assess the quality of the available evidence on the cost-
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …
A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
CTT Nguyen, F Petrelli, S Scuri… - … Journal of Health …, 2019 - search.proquest.com
Objective To review and assess the quality of the available evidence on the cost-
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …
A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-smallcell lung cancer
CTT Nguyen, F Petrelli, S Scuri, BT Nguyen… - The European Journal of …, 2019 - JSTOR
Objective To review and assess the quality of the available evidence on the cost-
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …
A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
CTT Nguyen, F Petrelli, S Scuri… - THE EUROPEAN …, 2019 - pubblicazioni.unicam.it
Objective To review and assess the quality of the available evidence on the cost-
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …
A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer.
CTT Nguyen, F Petrelli, S Scuri, BT Nguyen… - … European Journal of …, 2019 - europepmc.org
Objective To review and assess the quality of the available evidence on the cost-
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …
A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
CTT Nguyen, F Petrelli, S Scuri… - … Journal of Health …, 2019 - econpapers.repec.org
Objective To review and assess the quality of the available evidence on the cost-
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …
A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
CTT Nguyen, F Petrelli, S Scuri… - … journal of health …, 2019 - pubmed.ncbi.nlm.nih.gov
Objective To review and assess the quality of the available evidence on the cost-
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …
A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
CTT Nguyen, F Petrelli, S Scuri, BT Nguyen… - … European Journal of …, 2019 - ideas.repec.org
Objective To review and assess the quality of the available evidence on the cost-
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …